10x Genomics, Inc. (TXG) Stock Analysis

Q: What is the TXG stock price target?

Take-profit $25.92 (+19.7% upside). Prior stop was $20.13.

Q: What are the risks of investing in TXG?

Concentration risk — Product: Chromium solutions; Analyst target reached - limited upside remaining; Earnings in 7 days (event risk); Target reached (-3.6% upside); Momentum score 2.5/10 — below 4.5 minimum.

Q: Is TXG overvalued or undervalued?

10x Genomics, Inc. trades at a P/E of N/A (forward 101.0). TrendMatrix value score: 5.8/10. Overall verdict: Sell.

Q: What do analysts say about TXG?

22 analysts cover TXG with a consensus score of 3.6/5. Average price target: $24.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Health Information Services

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

10x Genomics develops instruments, consumables, and software for single-cell and spatial genomics analysis, having sold 8,046 instruments since 2015. Revenue of $642.8M in 2025 is primarily from Chromium single-cell and Visium/Xenium spatial platform consumables and instruments... Read more

$21.64+19.7% A.UpsideScore 4.9/10#11 of 13 Health Information Services

Stop $20.13Target $25.92(resistance)A.R:R -0.3:1

Analyst target$24.00+10.9%13 analysts

$25.92our TP

$21.64price

$24.00mean

$17

$32

Sell if holding. Analyst target reached at $21.64 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Chromium solutions. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

Strong earnings beat streak (4/4)

Earnings estimates trending UP

Risks

Concentration risk — Product: Chromium solutions

Analyst target reached - limited upside remaining

Earnings in 7 days (event risk)

Key Metrics

P/E (TTM)—

P/E (Fwd)101.0

Mkt Cap$2.6B

EV/EBITDA-33.4

Profit Mgn-6.8%

ROE-5.8%

Rev Growth0.6%

Beta2.17

DividendNone

Rating analysts22

Quality Signals

Piotroski F8/9

Options Flow

P/C0.36bullish

IV105%elevated

Max Pain$10-53.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductChromium solutions
10-K Item 1A: 'Our dependency on revenue generated from the sale of our Chromium solutions'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.815%0.87

Quality4.415%0.66

Growth6.315%0.94

Momentum2.510%0.25

Sentiment6.710%0.67

Insider Activity3.810%0.38

Peer Rank1.910%0.19

Technical Setup6.15%0.30

Risk Profile3.85%0.19

Catalyst7.95%0.40

Overall (Σ contributions)4.86

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.0

Quality Rank

2.0

Value Rank

5.4

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.5<4.5A.R:R -0.2=NEGATIVEEARNINGS PROXIMITY 7d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

43 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.53Resistance $26.45

Price Targets

$20

$26

A.Upside+19.8%

A.R:R-0.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-3.6% upside)

! Momentum score 2.5/10 — below 4.5 minimum

! Negative risk/reward — downside exceeds upside

Earnings

4/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is TXG stock a buy right now?

Sell if holding. Analyst target reached at $21.64 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Chromium solutions. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $20.13. Score 4.9/10, moderate confidence.

What is the TXG stock price target?

Take-profit target: $25.92 (+19.7% upside). Prior stop was $20.13. Stop-loss: $20.13.

What are the risks of investing in TXG?

Concentration risk — Product: Chromium solutions; Analyst target reached - limited upside remaining; Earnings in 7 days (event risk).

Is TXG overvalued or undervalued?

10x Genomics, Inc. trades at a P/E of N/A (forward 101.0). TrendMatrix value score: 5.8/10. Verdict: Sell.

What do analysts say about TXG?

22 analysts cover TXG with a consensus score of 3.6/5. Average price target: $24.

What does 10x Genomics, Inc. do?10x Genomics develops instruments, consumables, and software for single-cell and spatial genomics analysis, having sold...